Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme. The collaboration and investmen ...

Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...

Illumina (ILMN) and MyOme announced a collaboration and investment by Illumina into MyOme. The collaboration and investment will help advance ...

With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...

Illumina (ILMN) has been grinding higher over the past month, even though the stock is still down over the past year, raising a simple question for investors: is this quiet rebound worth leaning into?

Single-cell sequencing provides unprecedented detail into cell-to-cell variability, uncovering key biological mechanisms in ...

Former deputy prime minister, who left Meta this year, to be joined by Facebook-owner’s chief AI scientist ...

The 24th HUPO World Congress showed a field growing beyond mass spectrometry and starting to think in terms of impact of its ecosystems.

The global genomics market is projected to expand by 15-17% by 2029. Key factors driving this growth include the increasing ...

The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...

Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...